September 24, 2019

UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer

September 24, 2019

UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances

September 19, 2019

Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

August 7, 2019

Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D.

August 5, 2019

Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer

July 18, 2019

Kronos Bio Completes $105 Million Series A Financing

July 16, 2019

Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform

June 4, 2019

Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy

May 1, 2019

Allogene Therapeutics Announces Expansion of Scientific Advisory Board

April 15, 2019

Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma

January 28, 2019

Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy

January 8, 2019

UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

January 3, 2019

UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer

December 4, 2018

Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

November 28, 2018

Kronos Bio Appoints Philip Gutry as Chief Business Officer to Expand Pipeline Opportunities

October 15, 2018

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 10, 2018

Allogene Therapeutics Announces Pricing of Initial Public Offering

October 2, 2018

FierceBiotech names Kronos Bio as one of its “Fierce 15” Biotech Companies of 2018

September 27, 2018

Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

September 14, 2018

Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

September 6, 2018

Allogene Therapeutics Completes a $120 Million Private Financing

August 28, 2018

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality

August 14, 2018

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

July 10, 2018

Allogene Therapeutics Announces Scientific Advisory Board

June 18, 2018

Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer